Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 8 for:    FDL169 | Cystic Fibrosis

Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02767297
Recruitment Status : Completed
First Posted : May 10, 2016
Last Update Posted : October 24, 2016
Sponsor:
Information provided by (Responsible Party):
Flatley Discovery Lab LLC

Brief Summary:
To determine the relative bioavailability of the capsule (reference) and tablet (test) formulations of FDL169 in healthy adult males and females, and to evaluate the pharmacokinetic (PK) profile FDL169 tablets (test formulation) in both healthy adult males and females, and subjects with cystic fibrosis (CF).

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: FDL169 Phase 1 Phase 2

Detailed Description:

This is a three-part study.

Part 1:

Part 1 of the study is a single dose, open-label, randomized crossover study in healthy male and female subjects to compare the relative bioavailability of two formulations of FDL169.

Part 2:

Part 2 of the study is a multiple, escalating dose study of three different doses of the test formulation of FDL169 in healthy male and female subjects to evaluate the PK profile of the test formulation of FDL169.

Part 3:

Part 3 of the study is a single dose, open-label study in male and female subjects with CF to determine the PK profile of the test formulation of FDL169.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: A Three-Part Phase 1b Bioavailability and Pharmacokinetics Study of Two Formulations of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis
Study Start Date : April 2016
Actual Primary Completion Date : October 2016
Actual Study Completion Date : October 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Arm Intervention/treatment
Experimental: Part 1: Single dose (cross over)
FDL169 reference formulation and test formulation administered as a single dose in healthy subjects
Drug: FDL169
Experimental: Part 2: Multiple dose (dose level 1)
FDL169 test formulation (Dose level 1) administered as repeat doses in healthy subjects
Drug: FDL169
Experimental: Part 2: Multiple dose (dose level 2)
FDL169 test formulation (Dose level 2) administered as repeat doses in healthy subjects
Drug: FDL169
Experimental: Part 2: Multiple dose (dose level 3)
FDL169 test formulation (Dose level 3) administered as repeat doses in healthy subjects
Drug: FDL169
Experimental: Part 3: Single dose
FDL169 test formulation administered as a single dose in CF subjects
Drug: FDL169



Primary Outcome Measures :
  1. Part 1: Maximum plasma concentration of FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 72 h post-dose ]
  2. Part 1: Time to maximum plasma concentration of FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 72 h post-dose ]
  3. Part 1: Individual estimate of the terminal elimination rate constant of FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 72 h post-dose ]
  4. Part 1: Terminal half-life of FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 72 h post-dose ]
  5. Part 1: AUC from the time of dosing to the time of the last observed concentration for FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 72 h post-dose ]
  6. Part 1: AUC extrapolated to infinity from dosing time, based on the last observed concentration for FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 72 h post-dose ]
  7. Part 1: Clearance of FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 72 h post-dose ]
  8. Part 1: AUC% extrapolated for FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 72 h post-dose ]
  9. Part 2: Maximum plasma concentration of FDL169 (and metabolites) following multiple oral doses of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post last dose ]
  10. Part 2: Time to maximum plasma concentration of FDL169 (and metabolites) following multiple oral doses of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post last dose ]
  11. Part 2: Individual estimate of the terminal elimination rate constant of FDL169 (and metabolites) following multiple oral doses of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post last dose ]
  12. Part 2: Terminal half-life of FDL169 (and metabolites) following multiple oral doses of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post last dose ]
  13. Part 2: AUC from the time of dosing to the time of the last observed concentration for FDL169 (and metabolites) following multiple oral doses FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post last dose ]
  14. Part 2: AUC extrapolated to infinity from dosing time, based on the last observed concentration for FDL169 (and metabolites) following multiple oral doses of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post last dose ]
  15. Part 2: Clearance of FDL169 (and metabolites) following multiple oral doses of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post last dose ]
  16. Part 2: AUC% extrapolated for FDL169 (and metabolites) following multiple oral doses of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post last dose ]
  17. Part 3: Maximum plasma concentration of FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post-dose ]
  18. Part 3: Time to maximum plasma concentration of FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post-dose ]
  19. Part 3: Individual estimate of the terminal elimination rate constant of FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post-dose ]
  20. Part 3: Terminal half-life of FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post-dose ]
  21. Part 3: AUC from the time of dosing to the time of the last observed concentration for FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post-dose ]
  22. Part 3: AUC extrapolated to infinity from dosing time, based on the last observed concentration for FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post-dose ]
  23. Part 3: Clearance of FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post-dose ]
  24. Part 3: AUC% extrapolated for FDL169 (and metabolites) following single oral dose of FDL169 [ Time Frame: Multiple points from pre-dose to 48 h post-dose ]

Secondary Outcome Measures :
  1. Number of subjects with clinically significant changes in systolic and diastolic blood pressure following single and multiple oral doses of FDL169 [ Time Frame: Multiple points from screening to follow-up (7 days after last dose) ]
  2. Number of subjects with clinically significant changes in heart rate following single and multiple oral doses of FDL169 [ Time Frame: Multiple points from screening to follow-up (7 days after last dose) ]
  3. Number of subjects with clinically significant changes in oral temperature following single and multiple oral doses of FDL169 [ Time Frame: Multiple points from screening to follow-up (7 days after last dose) ]
  4. Number of subjects with clinically significant changes in oxygen saturation following single and multiple oral doses of FDL169 [ Time Frame: Multiple points from screening to follow-up (7 days after last dose) ]
  5. Number of subjects with clinically significant 12-lead ECG abnormalities following single and multiple oral doses of FDL169 [ Time Frame: Multiple points from screening to follow-up (7 days after last dose) ]
  6. Number of subjects with abnormal laboratory values following single and multiple oral doses of FDL169 [ Time Frame: Multiple points from screening to follow-up (7 days after last dose) ]
  7. Number of subjects experiencing treatment-related adverse events following single and multiple oral doses of FDL169 [ Time Frame: Multiple points from screening to follow-up (7 days after last dose) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Parts 1 and 2:

  1. Healthy, males and females between 18 and 55 years of age, inclusive, with a BMI of >19 and <30 kg/m2.
  2. If sexually active, must meet the contraception requirements.

Part 3:

  1. Male and female subjects aged 18 years and older.
  2. If sexually active, must meet the contraception requirements.
  3. Diagnosis of CF.
  4. History of pancreatic insufficiency.
  5. Forced expiratory volume in 1 second (FEV1) ≥40% of predicted normal for age, sex and height at screening.

Exclusion Criteria:

Parts 1 and 2:

  1. Prior or ongoing medical condition, medical history, physical findings, ECG findings or laboratory abnormality that could adversely affect the safety of the subject.
  2. Alkaline phosphatase, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) level >1.5 x upper limit of normal (ULN) at screening.
  3. Use of prescription or non-prescription drugs within 21 days or five half-lives (whichever is longer) before the first dose of study medication, unless the medication will not interfere with the study procedures or compromise subject safety.
  4. Pregnant or nursing females.
  5. Serum creatinine or total bilirubin >1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%).
  6. History of prolonged QT and/or QTcF interval.
  7. ECG with a single QTcF >450 msec in males, >460 msec in females, at Screening.
  8. Positive urinary drugs of abuse screen at Screening or Day -1, or positive alcohol screen at Day -1.
  9. History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units.
  10. History of human immunodeficiency virus (HIV) or positive HIV, hepatitis B or hepatitis C results at screening.
  11. Donation of 500 mL or more blood within 3 months before Day -1.
  12. Participation in a clinical trial involving receipt of an investigational product within the past 90 days or exposure to more than four new chemical entities with 12 months of the first dosing day.
  13. Current smoking or use of tobacco products or substitutes. Former smokers will be eligible, provided they have not smoked for at least 6 months before Day -1.
  14. Use of any prescription and non-prescription medications that are inhibitors or inducers of cytochrome P450 (CYP) 3A4 within 7 days before Day -1.

Part 3:

  1. History of any illness, or ongoing acute illness that could impact the safety of the subject or confound study results.
  2. Abnormal liver function ≥3 x ULN: AST, ALT, total bilirubin.
  3. A pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks prior to the Baseline (Day 1) Visit
  4. Use of herbal and dietary supplements within 21 days or five half-lives (whichever is longer) before the first dose of study medication, unless the medication will not interfere with the study procedures or compromise subject safety.
  5. Pregnant or nursing females.
  6. Serum creatinine or total bilirubin >1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%).
  7. History of prolonged QT and/or QTcF interval.
  8. ECG with a single QTcF >450 msec in males, >460 msec in females, at Screening.
  9. Positive urinary drugs of abuse screen at Screening or Day -1, or positive alcohol screen at Day -1.
  10. History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units.
  11. History of HIV, or positive HIV, hepatitis B or hepatitis C results at screening.
  12. Donation of 500 mL or more blood within 3 months before Day -1.
  13. Participation in a clinical trial involving receipt of an investigational product within the past 90 days or exposure to more than four new chemical entities with 12 months of the first dosing day.
  14. Current smoking or use of tobacco products or substitutes. Former smokers will be eligible, provided they have not smoked for at least 6 months before Day -1.
  15. Use of any prescription and non-prescription medications that are inhibitors or inducers of CYP3A4, within 7 days before Day -1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02767297


Locations
Layout table for location information
United Kingdom
Celerion
Belfast, United Kingdom, BT9 6AD
Sponsors and Collaborators
Flatley Discovery Lab LLC
Investigators
Layout table for investigator information
Principal Investigator: Stuart Elborn, MD Queen's University

Layout table for additonal information
Responsible Party: Flatley Discovery Lab LLC
ClinicalTrials.gov Identifier: NCT02767297     History of Changes
Other Study ID Numbers: FDL169-2015-03
First Posted: May 10, 2016    Key Record Dates
Last Update Posted: October 24, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases